White House Proposes Wastewater Testing and AI to Track Drug Use in Real Time

The Trump administration is preparing to unveil a comprehensive drug control strategy that would deploy wastewater testing nationwide to track illegal drug consumption in real time, while using artificial intelligence to screen cargo and identify patients at high risk of overdose.

The 195-page document, set for release next week according to sources familiar with the matter, represents a significant expansion of surveillance capabilities in the service of drug policy. It arrives at a moment of contradictory trends: overdose deaths are declining from their mid-2023 peak, yet drug use among Americans continues to tick upward, driven largely by increased marijuana consumption.

A New Surveillance Architecture

The strategy's most novel element is a proposed national wastewater-based monitoring system. By analyzing sewage for drug metabolites, public health officials could track consumption patterns with geographic precision and minimal lag time—potentially identifying emerging drug threats before they appear in overdose statistics.

"We will also prioritize establishing new data systems to monitor drug consumption in real-time, through a national wastewater-based monitoring system and biosurveillance," the draft document states. "These objective measures will provide timely, localized data on current drug use and trafficking patterns."

Wastewater epidemiology has gained traction internationally as a complement to traditional survey methods. European cities have used sewage analysis to track everything from cocaine consumption to COVID-19 prevalence. The approach offers advantages over self-report surveys: it captures actual consumption rather than reported behavior, cannot be biased by social desirability effects, and provides data at the population level without requiring individual participation.

However, expanding such monitoring to a national scale raises significant logistical and privacy questions. The strategy document does not specify how the system would be funded, which jurisdictions would participate, or how data would be shared between federal agencies and local health departments.

Artificial Intelligence Applications

Beyond wastewater, the strategy envisions multiple applications for artificial intelligence in drug control. At ports of entry, AI would screen cargo for illicit drugs—a potentially significant enhancement given the volume of fentanyl and precursor chemicals entering through commercial shipping. The document also proposes using AI to examine electronic health records to identify patients at high risk of overdose, and to develop search algorithms for detecting emerging drug threats.

These applications sit at the intersection of public health surveillance and law enforcement, raising questions about data access and patient privacy. Using electronic health records for overdose prediction would require navigating HIPAA regulations and obtaining patient consent—or operating under specific public health exemptions that allow disclosure without individual authorization.

The strategy does not specify which AI systems would be deployed, how they would be validated, or what safeguards would prevent misuse of the sensitive data involved. These details will likely become clearer when the final document is released.

Faith and Treatment

The document places significant emphasis on faith-based approaches to addiction treatment, marking a departure from the secular framework that has dominated federal drug policy in recent decades.

"Secular education and treatment are important, but for those who have faith, adding God into the equation brings in a special power," the report states. It encourages faith leaders to "use their influence and pulpit to promote the social norm of not using drugs and bringing hope and support to those who have the treatable condition of addiction."

This emphasis aligns with the administration's broader prioritization of religious institutions in social service delivery. The strategy calls for expanded treatment accessibility, stating that it "should be easier to access treatment than it is to buy illicit drugs." It supports medication-based treatment for opioid use disorder while also calling for research into similar treatments for methamphetamine, cocaine, and marijuana.

The integration of addiction care with general medical care receives endorsement in the document, which advocates for "individualized and comprehensive" treatment approaches. This aligns with consensus recommendations from major medical organizations, though the faith-based emphasis represents a distinctive overlay.

Harm Reduction in Tension

The strategy includes language supporting some harm reduction measures while the administration simultaneously restricts others. Naloxone, the overdose-reversing medication, "must be as common as having epinephrine to treat an allergic reaction," the document states. Fentanyl test strips are described as an "important tool" for detecting contaminated drugs.

Yet this rhetoric sits uneasily with recent policy actions. SAMHSA recently informed grant recipients that federal funds cannot be used to purchase fentanyl test strips or syringes—a significant restriction on harm reduction activities that many public health experts consider essential for preventing overdose deaths.

The tension reflects broader debates within the administration and Congress about the proper balance between reducing drug-related harms and discouraging drug use itself. Critics of harm reduction argue that providing tools for safer use enables continued drug consumption, while proponents counter that abstinence-only approaches have failed to prevent tens of thousands of annual deaths.

The Context of Declining Deaths

The strategy arrives as overdose deaths are finally declining after years of relentless increase. According to federal data, approximately 68,000 Americans died of drug overdoses in the 12-month period ending in November—still catastrophically high, but down from the mid-2023 peak.

This decline likely reflects multiple factors: expanded access to naloxone, increased availability of medication-assisted treatment for opioid use disorder, and shifts in the illicit drug supply. Fentanyl remains the primary driver of overdose deaths, but its dominance may have stabilized as users and dealers adapt to its presence.

At the same time, the 2024 National Survey on Drug Use and Health found that more Americans reported using illicit drugs in the past year, primarily due to increased marijuana use. The strategy document reflects concern about this trend, accusing marketers of addictive substances of adopting "strategies similar to Big Tobacco's historical targeting of young audiences" and criticizing pop culture for normalizing drug use.

Supply-Side Pressure

The strategy maintains the administration's emphasis on disrupting drug supply chains through law enforcement and foreign policy. The document cites the designation of certain cartels as foreign terrorist organizations and military strikes on alleged drug boats as elements of this approach.

Whether such measures can meaningfully reduce drug availability remains contested. Decades of supply-side enforcement have failed to prevent the emergence of new synthetic drugs or the proliferation of fentanyl, which is cheap to manufacture and easy to transport. Some public health experts argue that demand reduction and harm reduction offer more promising paths than interdiction.

The strategy's proposed surveillance systems—wastewater monitoring and AI cargo screening—represent attempts to make supply-side efforts more targeted and efficient. Whether they can succeed where previous approaches have failed will depend on implementation details not yet available.

What Comes Next

The document's release next week will provide clarity on funding allocations, implementation timelines, and specific programmatic commitments. The draft obtained by CBS News did not include budget figures, leaving open the question of whether proposed surveillance systems and treatment expansions will receive appropriations sufficient for meaningful implementation.

Congressional response will shape the strategy's ultimate impact. Some elements—particularly the faith-based emphasis and surveillance expansions—may face opposition from Democrats, while Republicans may question the continued support for medication-assisted treatment and certain harm reduction measures.

For public health officials and treatment providers, the strategy offers both opportunities and concerns. New data systems could improve targeting of prevention and treatment resources. Expanded treatment access could help address persistent gaps in care. But restrictions on harm reduction tools and the emphasis on faith-based approaches may limit effectiveness for populations that do not respond to religious messaging.

The coming months will reveal whether this strategy represents a genuine evolution in federal drug policy or a reshuffling of existing approaches under new rhetorical framing. With tens of thousands of lives still being lost to overdose annually, the stakes for getting that evolution right could not be higher.